Rosa to present at 2012 Keystone Symposia: Cancer and Metabolism
Modeling analysis enables understanding efficacy of large numbers of potential drug combinations.

SAN CARLOS, CA, February 02, 2012 /24-7PressRelease/ -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that the results from a recent research project will be presented at the 2012 Keystone Symposia: "Cancer and Metabolism" in Banff, Alberta, Canada on February 13, 2012. Dr. Christiana Friedrich will be presenting a poster entitled "Combination Therapy in Virtual NSCLC Tumor Cells Supports Strategic Development and Treatment Decisions". The poster will describe the development and use of non-small cell lung cancer in silicocells to explore clinical variability in response to a range of cancer treatments. The main benefit of this approach is that it allows the analysis and prioritization of a large number of potential combination therapies, prior to initiation of expensive and time-consuming studies in humans. This work will also highlight the use of a Tumor PhysioPD model to gain additional insight into tumor dynamics and to optimize treatment in a range of in silico tumors.

"This work supports fundamental insights into tumor dynamics in response to therapies and the effects of patient variability," said Dr. Mike Reed, Rosa's Vice President of Client Services. "This work lays the foundation for a mechanism-informed personalized medicine approach to optimize cancer treatment in the clinic, and more efficient ways to study large numbers of potential combination therapies.

Press Release Contact Information:

Rebecca Baillie
Rosa & Co
Chief Scientist
751 Laurel St., Ste. 127
San Carlos, CA
USA 94070
Voice: 530-661-7476
Website: Visit Our Website